Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DW7N | ISIN: IE00BF0L3536 | Ticker-Symbol: A5G
Tradegate
22.01.25
11:29 Uhr
5,540 Euro
-0,035
-0,63 %
1-Jahres-Chart
AIB GROUP PLC Chart 1 Jahr
5-Tage-Chart
AIB GROUP PLC 5-Tage-Chart
RealtimeGeldBriefZeit
5,5405,63512:11
5,5355,63012:11
GlobeNewswire (Europe)
281 Leser
Artikel bewerten:
(1)

Delisting of Securities of PHP Ventures Acquisition Corp.; Green Giant Inc.; RMG Acquisition Corp. III; Biophytis SA; OMNIQ Corp.; AIB Acquisition Corporation; Goal Acquisitions Corp.; Applied UV, Inc.; Cue Health Inc. and others

Finanznachrichten News

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, rights, warrants, and units of PHP Ventures Acquisition Corp. PHP Ventures Acquisition Corp.'s securities were suspended on April 19, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Green Giant Inc. Green Giant Inc.'s securities were suspended on April 19, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares, warrants, and units of RMG Acquisition Corp. III. RMG Acquisition Corp. III's securities were suspended on April 23, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the American Depositary Shares of Biophytis SA. Biophytis SA's securities were suspended on April 26, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of OMNIQ Corp. OMNIQ Corp.'s securities were suspended on May 7, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the ordinary shares, rights, and units of AIB Acquisition Corporation. AIB Acquisition Corporation's securities were suspended on May 9, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock, warrants and units of Goal Acquisitions Corp. Goal Acquisitions Corp.'s securities were suspended on May 23, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common and preferred stock of Applied UV, Inc. Applied UV, Inc.'s securities were suspended on June 4, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Cue Health Inc. Cue Health Inc.'s securities were suspended on June 6, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Class A common stock, warrants, and units of Twelve Seas Investment Company II. Twelve Seas Investment Company II's securities were suspended on June 10, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of CalAmp Corp. CalAmp Corp.'s securities were suspended on June 12, 2024, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of ThermoGenesis Holdings, Inc. ThermoGenesis Holdings, Inc.'s securities were suspended on June 17, 2024, and have not traded on Nasdaq since that time.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq's rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.

-NDAQF-


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.